Article
Naturally Selected CD7 CAR-T Therapy without Genetic editing Exerts Significant Antitumor Efficacy against Relapsed and Refractory Acute Myeloid Leukemia(R/R-AML)
2022-10-10
Abstract excerpt
<title>Abstract</title><p>Background Survival time for patients with relapsed and refractory acute myeloid leukemia (R/R-AML) remains threatened and treatment appears challenging. Chimeric antigen receptor T cell (CAR-T) has been widely used for hematologic malignancies. Current CAR-T therapies for acute myeloid leukemia mostly target myeloid-lineage antigens such as CD123 and CD33, which may have potential hemato...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 9d8908ba-5575-58a6-abc6-067d07ad87df
- DOI
- 10.21203/rs.3.rs-2110527/v1
